Surgical approach as a determinant factor of clinical outcome following radical cystectomy: Does Enhanced Recovery After Surgery (ERAS) level the playing field?


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
10 2019
Historique:
received: 03 03 2019
revised: 28 05 2019
accepted: 03 06 2019
pubmed: 10 7 2019
medline: 17 9 2020
entrez: 10 7 2019
Statut: ppublish

Résumé

To determine whether surgical approach is a determinant of clinical outcomes following radical cystectomy (RC) and urinary diversion when using an Enhanced Recovery After Surgery (ERAS) protocol. We studied all patients undergoing both open radical cystectomy (ORC) and robotic-assisted radical cystectomy (RARC) and urinary diversion with ERAS for bladder urothelial carcinoma from May 2012 to December 2016. Surgical and clinical outcomes within 90 days after surgery were compared between ORC and RARC, including readmission and major complication rates (Clavien-Dindo grade ≥III). Multivariable logistic regression modeling was used to determine factors that predict readmission and major complications. A total of 345 and 143 patients underwent ORC and RARC, respectively. The ORC group had a greater proportion of continent urinary diversion (71.9 vs. 40.6%, P< 0.001), shorter operative time (5.4 vs. 7.3 hours, P< 0.001), higher estimated blood loss (500 vs. 200 ml, P< 0.001), and higher intraoperative and postoperative transfusion rates (20.9 vs. 9.1%, P= 0.002 and 20 vs. 11.9%, P= 0.04, respectively). Median length of stay was 4 days for ORC (interquartile range 4-6 days) and 6 days for RARC (interquartile range 4-7 days; P< 0.001). There was no significant difference between ORC and RARC groups in major complication rates (20 vs. 23.8%, P= 0.51) or readmission rates (32.2 vs. 36.4%, P= 0.4) within 90 days after surgery. Multivariable logistic regression analysis showed that surgical approach was not an independent factor predictive of readmission (P= 0.33) or major complications (P= 0.76). Surgical approach is not a determinant of readmission or major complications following RC in the context of an ERAS protocol.

Identifiants

pubmed: 31285114
pii: S1078-1439(19)30227-3
doi: 10.1016/j.urolonc.2019.06.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

765-773

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Jian Chen (J)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA.

Hooman Djaladat (H)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA.

Anne K Schuckman (AK)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA.

Monish Aron (M)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA.

Mihir Desai (M)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA.

Inderbir S Gill (IS)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA.

Thomas G Clifford (TG)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA.

Saum Ghodoussipour (S)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA.

Gus Miranda (G)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA.

Jie Cai (J)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA.

Siamak Daneshmand (S)

Catherine & Joseph Aresty Department of Urology, University of Southern California Institute of Urology, Los Angeles, CA. Electronic address: daneshma@med.usc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH